Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Medtronic
Dow
Baxter
Colorcon

Last Updated: May 26, 2022

Bionpharma Inc Company Profile


✉ Email this page to a colleague

« Back to Dashboard

What is the competitive landscape for BIONPHARMA INC, and what generic alternatives to BIONPHARMA INC drugs are available?

BIONPHARMA INC has forty-eight approved drugs.

There are five US patents protecting BIONPHARMA INC drugs.

There are ten patent family members on BIONPHARMA INC drugs in thirteen countries and seventy-four supplementary protection certificates in fourteen countries.

Summary for Bionpharma Inc
International Patents:10
US Patents:5
Tradenames:45
Ingredients:41
NDAs:48
Drug Master File Entries: 2
Patent Litigation for Bionpharma Inc: See patent lawsuits for Bionpharma Inc

Drugs and US Patents for Bionpharma Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bionpharma Inc LOPERAMIDE HYDROCHLORIDE loperamide hydrochloride CAPSULE;ORAL 021855-001 Aug 4, 2005 OTC Yes No See Plans and Pricing See Plans and Pricing
Bionpharma Inc DOFETILIDE dofetilide CAPSULE;ORAL 208625-002 Apr 10, 2018 AB RX No No See Plans and Pricing See Plans and Pricing
Bionpharma Inc IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE diphenhydramine hydrochloride; ibuprofen CAPSULE;ORAL 090397-001 Nov 22, 2010 OTC No No See Plans and Pricing See Plans and Pricing
Bionpharma Inc FLUVOXAMINE MALEATE fluvoxamine maleate CAPSULE, EXTENDED RELEASE;ORAL 212182-002 Sep 16, 2020 AB RX No No See Plans and Pricing See Plans and Pricing
Bionpharma Inc DROXIDOPA droxidopa CAPSULE;ORAL 213033-002 Apr 28, 2021 AB RX No No See Plans and Pricing See Plans and Pricing
Bionpharma Inc AMPHETAMINE SULFATE amphetamine sulfate TABLET;ORAL 212919-002 Nov 22, 2019 AA RX No No See Plans and Pricing See Plans and Pricing
Bionpharma Inc ZONISAMIDE zonisamide CAPSULE;ORAL 077813-003 Aug 16, 2006 AB RX No No See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for Bionpharma Inc Drugs

Country Patent Number Estimated Expiration
Portugal 1863458 See Plans and Pricing
Poland 1863458 See Plans and Pricing
Mexico 2007011039 See Plans and Pricing
China 102940887 See Plans and Pricing
World Intellectual Property Organization (WIPO) 2006096580 See Plans and Pricing
European Patent Office 3061447 See Plans and Pricing
Canada 2600023 See Plans and Pricing
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Bionpharma Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0716606 SPC/GB02/011 United Kingdom See Plans and Pricing PRODUCT NAME: SEVELAMER; REGISTERED: UK EU/1/99/120/001-004 20000202
0914118 SPC/GB07/002 United Kingdom See Plans and Pricing SUPPLEMENTARY PROTECTION CERTIFICATE NO SPC/GB07/002 GRANTED TO NOVARTIS AG IN RESPECT OF THE PRODUCT DEFERASIROX AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, ESPECIALLY 4-(3,5-BIS(2-HYDROXYPHENYL)-(1,2,4) TRIAZOL-L-YL) BENZOIC ACID, THE GRANT OF WHICH WAS ADVERTISED IN JOURNAL NO 6179 DATED 24 OCTOBER 2007 HAS HAD ITS MAXIMUM PERIOD OF DURATION CORRECTED, SUBJECT TO THE PAYMENT OF THE PRESCRIBED FEES IT WILL EXPIRE ON 30 AUGUST 2021.
0716606 C300428 Netherlands See Plans and Pricing PRODUCT NAME: SEVELAMER CARBONAAT OF BICARBONAAT; REGISTRATION NO/DATE: EU/1/09/521/001-007 20090610
0245997 C300002 Netherlands See Plans and Pricing PRODUCT NAME: DOFETILIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT; REGISTRATION NO/DATE: EU/1/99/121/001 - EU/1/99/121/015 19991129
1441735 08C0026 France See Plans and Pricing PRODUCT NAME: RALTEGRAVIR POTASSIUM; REGISTRATION NO/DATE: EU/1/07/436/001 20080102
1441735 2008/010 Ireland See Plans and Pricing PRODUCT NAME: RALTEGRAVIR OR A PHARMECEUTICALLY ACCEPTABLE SALT THEREOF, ESPECIALLY THE POTASSIUM SALT; NAT AUTHORISTION NO/DATE: EU/1/07/436/001-002 20071220;
0984957 PA2011005,C0984957 Lithuania See Plans and Pricing PRODUCT NAME: NAPROXENUM + ESOMEPRAZOLUM; REGISTRATION NO/DATE: LT/1/10/2302/001-LT/1/10/2302/012 20110126
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Dow
Baxter
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.